Susquehanna International Group
FDMT icon

Susquehanna International Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Susquehanna International Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Sell
124,228
-1,785
-1% -$15.5K ﹤0.01% 7501
2025
Q4 		$945K Sell
126,013
-6,799
-5% -$69K ﹤0.01% 7319
2025
Q3 		$1.15M Buy
132,812
+8,013
+6% +$47.9K ﹤0.01% 7009
2025
Q2 		$463K Buy
124,799
+54,079
+76% +$190K ﹤0.01% 9350
2025
Q1 		$228K Buy
70,720
+37,991
+116% +$179K ﹤0.01% 10668
2024
Q4 		$182K Buy
32,729
+7,956
+32% +$62.4K ﹤0.01% 10826
2024
Q3 		$268K Sell
24,773
-9,250
-27% -$154K ﹤0.01% 9835
2024
Q2 		$714K Buy
34,023
+17,431
+105% +$437K ﹤0.01% 7364
2024
Q1 		$529K Sell
16,592
-23,890
-59% -$609K ﹤0.01% 8372
2023
Q4 		$820K Buy
40,482
+20,142
+99% +$265K ﹤0.01% 7470
2023
Q3 		$259K Sell
20,340
-2,208
-10% -$36.9K ﹤0.01% 9673
2023
Q2 		$407K Sell
22,548
-56,026
-71% -$1.03M ﹤0.01% 8789
2023
Q1 		$1.35M Buy
78,574
+46,348
+144% +$901K ﹤0.01% 6064
2022
Q4 		$716K Buy
32,226
+21,668
+205% +$335K ﹤0.01% 6967
2022
Q3 		$85K Buy
10,558
+155
+1% +$1.4K ﹤0.01% 11824
2022
Q2 		$73K Sell
10,403
-9,953
-49% -$96.8K ﹤0.01% 11739
2022
Q1 		$308K Sell
20,356
-13,500
-40% -$212K ﹤0.01% 10212
2021
Q4 		$743K Buy
+33,856
New +$830K ﹤0.01% 8087

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Susquehanna International Group's FDMT Position: Q1 2026 in Review

Susquehanna International Group reduced its 4D Molecular Therapeutics (FDMT) stake by 1.4% in Q1 2026, selling an estimated $15.5K and leaving 124,228 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #7501.

Susquehanna International Group first reported a position in FDMT in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.35M in Q1 2023. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Susquehanna International Group held 124,228 shares of 4D Molecular Therapeutics worth $1.16M as of Q1 2026.
  • Susquehanna International Group sold 1,785 4D Molecular Therapeutics shares in Q1 2026, an estimated $15.5K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7501 holding.
  • Susquehanna International Group first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Susquehanna International Group's 4D Molecular Therapeutics position peaked at $1.35M in Q1 2023.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.